Picture Berlin Partner Join Cluster HealthCapital Berlin Brandenburg 650x100px

Organisation › Details

Asahi Glass (AGC) (Group)

https://www.agc.co.jp

	Start	1997-10-01 existent
	End	1997-10-01 existent
	Industry	glass and glass containers (laboratory)

	City	n. a.
		Address record changed: 2020-12-02

Basic data	Employees	n. a.


		Record changed: 2024-08-24

Picture Berlin Partner Voices Uirá Souto Melo Lucid Genomics 650x200px

More documents for Asahi Glass (AGC) (Group)

[1] AGC Biologics. (8/7/24). "Press Release: NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines"....
[2] AGC Biologics. (9/13/21). "Press Release: AGC Biologics Expands pDNA and mRNA Manufacturing Capacity at Heidelberg Facility". Heidelberg....
[3] AGC Biologics. (8/20/21). "Press Release: AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site". Copenhagen....
[4] MolMed S.p.A.. (4/14/20). "Press Release: MolMed: the Board of Directors, Based on the Scientific Evidence from the Experiments on Early-stage Pre-clinical Products, Decided to Suspend the Investments in These Projects". Milan....
[5] MolMed S.p.A. (at the request of AGC Inc.). (4/2/20). "Press Release: Offer Document Filed with Consob. Voluntary Public Tender Offer Launched by AGC Inc. on All the Ordinary Shares of MolMed S.p.A. [Not for release where violation of laws or regulations...
[6] AGC Inc.. (3/17/20). "Press Release: AGC Decides to Launch Voluntary Tender Offer for Shares of MolMed"....
[7] MolMed S.p.A.. (3/9/20). "Press Release: The Board of Directors Approved the 2019 Full Year Financial Results". Milan....
[8] MolMed S.p.A.. (3/6/20). "Press Release: MolMed Signs a Multi-year Agreement and Announces the Beginning of a New Collaboration in the Field of T Cell Therapies". Milan....
[9] MolMed S.p.A.. (12/18/19). "Press Release: Italy – the EIB Supports MolMed Investment in Research, Development and Manufacturing for Cancer and Rare Diseases Innovative Treatments". Oxford....
[10] MolMed S.p.A.. (10/10/19). "Press Release: MolMed Informs on Its Decision to Withdraw the Conditional Marketing Authorization of Zalmoxis". Milan....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]